Back to top
more

Surrozen (SRZN)

(Delayed Data from NSDQ)

$10.00 USD

10.00
736

-0.10 (-0.99%)

Updated May 3, 2024 03:59 PM ET

After-Market: $9.83 -0.17 (-1.70%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (143 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Catalent (CTLT) to Report Q3 Earnings: What's in the Cards? (Revised)

by Zacks Equity Research

Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.

Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Harrow Health's (HROW) first-quarter top line is likely to have been driven by its recent product launches.

Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.

Here's Why Surrozen, Inc. (SRZN) Could be Great Choice for a Bottom Fisher

by Zacks Equity Research

Surrozen, Inc. (SRZN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Revvity (PKI) to Report Q1 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

Revvity's (PKI) first-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.

DaVita (DVA) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

High labor costs and inflationary pressures are likely to have weighed on DaVita's (DVA) first-quarter top line.

BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited Q2 sales.

What Awaits Lantheus Holdings (LNTH) This Earnings Season?

by Zacks Equity Research

Lantheus Holdings' (LNTH) first-quarter results are likely to reflect solid top-line results on the back of robust product adoption.

Zacks.com featured highlights include Lamb Weston, NeoGenomics, Surrozen, KE Holdings and Insperity

by Zacks Equity Research

Lamb Weston, NeoGenomics, Surrozen, KE Holdings and Insperity are part of the Zacks Screen of the Week article.

Here's Why You May Add Nektar (NKTR) Stock to Your Portfolio

by Zacks Equity Research

Here we discuss some reasons why investing in Nektar Therapeutics (NKTR) stock now is a good idea despite its several pipeline setbacks.

Sanghamitra Saha headshot

5 Top Stocks Likely to Come Up With Earnings Beat

by Sanghamitra Saha

These top-ranked stocks are likely to beat on the bottom line in their next releases. Tap Lamb Weston (LW), NeoGenomics (NEO), Surrozen (SRZN), KE Hodlings (BEKE) and Insperity (NSP).

Here's Why You Should Invest in Larimar (LRMR) Stock Now

by Zacks Equity Research

Here we discuss some reasons why investing in Larimar Therapeutics (LRMR) stock now is a good idea.

Here's Why You Can Add KalVista (KALV) Stock to Your Portfolio

by Zacks Equity Research

Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now is a good idea.

New Strong Buy Stocks for April 12th

by Zacks Equity Research

CELU, MGI, LRMR, EQRX and SRZN have been added to the Zacks Rank #1 (Strong Buy) List on April 12, 2023.

Surrozen, Inc. (SRZN) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Surrozen, Inc. (SRZN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.